CMC Biologics and OncoSynergy Form Pact - - BioPharm International

ADVERTISEMENT

CMC Biologics and OncoSynergy Form Pact



CMC Biologics and OncoSynergy have entered into an agreement for cell-line development, process development, analytical development, and manufacturing of non-GMP material to enable early toxicology testing and cGMP material for investigational new drug enabling toxicology studies and Phase I clinical trials. This work will advance OncoSynergy’s OS2966 monoclonal antibody program based on its “targeted synergy” approach–a strategy allowing broad inhibition of multiple fundamental cancer-growth mechanisms with a single drug.  The project will be executed by CMC Biologics at its Copenhagen development and manufacturing facility. OncoSynergy EU SAS in France will lead the project.

Source: CMC Biologics

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Novartis Sells Influenza Vaccine Business to CSL for $275 Million
October 27, 2014
Author Guidelines

Click here